Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study.

Atherosclerosis - 1 Sept 2009

Cardona Fernando, Guardiola Montserrat, Queipo-Ortuño María Isabel, Murri Mora, Ribalta Josep, Tinahones Francisco J

Abstract excerpt

OBJECTIVE: Apolipoprotein A5 is a key gene controlling VLDL synthesis and hydrolysis and is the target of the main pharmacological agent to lower triglycerides (fibrates). We hypothesised that variability in the promoter of the APOA5 gene may affect the individual response to fibrate therapy, in both the fasting and postprandial states. METHODS: We selected 50 subjects with the metabolic syndrome who also had...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein A-V
Share to Apolipoproteins A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dietary Fats

Share to Hypertriglyceridemia

Share to Lipids

Share to Metabolic Syndrome

Share to Postprandial Period

Share to Triglycerides

Source

Identifiers

PMID: 19344899
DOI: 10.1016/j.atherosclerosis.2009.02.024

Genes

APOA5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study.PMID 19344899Read ↗

Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.Semantic proximity Read ↗

Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges.Semantic proximity Read ↗

Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome.Semantic proximity Read ↗

Two independent apolipoprotein A5 haplotypes modulate postprandial lipoprotein metabolism in a healthy Caucasian population.Semantic proximity Read ↗

A promoter variant of the APOA5 gene increases atherogenic LDL levels and arterial stiffness in hypertriglyceridemic patients.Semantic proximity Read ↗

Effects of variations in the APOA1/C3/A4/A5 gene cluster on different parameters of postprandial lipid metabolism in healthy young men.Semantic proximity Read ↗

SNPs in Apolipoproteins Contribute to Sex-Dependent Differences in Blood Lipids Before and After A Dietary Challenge in Healthy U.S. AdultsSemantic proximity Read ↗

Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.Semantic proximity Read ↗

Comparison of low-fat meal and high-fat meal on postprandial lipemic response in non-obese men according to the -1131T>C polymorphism of the apolipoprotein A5 (APOA5) gene (randomized cross-over design).Semantic proximity Read ↗

APOA5-1131T>C genotype effects on apolipoprotein A5 and triglyceride levels in response to dietary intervention and regular exercise (DIRE) in hypertriglyceridemic subjects.Semantic proximity Read ↗

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.Semantic proximity Read ↗

APOA5 variants and metabolic syndrome in Caucasians.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.